Estradiol Patch
Product Images NDC 0378-3350

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Estradiol (NDC 0378-3350). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Estradiol Structural Formula (Image 01)

Chemical structure of estradiol hemihydrate, the active ingredient in Estradiol transdermal patches by Mylan Pharmaceuticals Inc.*

FDA Label Image

Transdermal Parts (Image 02)

An instructional diagram illustrating the layer structure of an estradiol transdermal patch. The layers, from top to bottom, include a foam backing with adhesive, a polyester film, an acrylate adhesive matrix containing estradiol, and a protective liner.*

FDA Label Image

Figure 1 Mean Serum 17β-estradiol Concentrations Vs. Time Profile Following Application Of A 7.75 Cm2 Transdermal Patch And Application Of A 15.5 Cm2 Estradiol Transdermal System Continuous Delivery (once-weekly) Patch (Image 03)

A line graph depicting estradiol concentrations (pg/mL) over time (hours) for two sizes of the Estradiol Transdermal System: 7.75 cm² and 3.25 cm². The graph shows concentration changes over a time span up to 180 hours with higher concentrations for the larger system.*

FDA Label Image

Figure 2 Observed Mean (± S.e.) Estradiol Serum Concentrations For A One Week Application Of The Estradiol Transdermal System Continuous Delivery (once-weekly) (31 Cm2) To The Abdomen And Buttocks Of 38 Postmenopausal Women (Image 04)

A line graph depicting mean concentration (pg/mL) over time (hours after patch application) for estradiol administered via patch. Two treatment sites, buttock and abdomen, are compared across multiple sampling times up to 192 hours post-application, with concentration-level error bars shown.*

FDA Label Image

Figure 3 Mean Percent Change From Baseline In Lumbar Spine (a-p View) Bone Mineral Density By Treatment And Time Last Observation Carried Forward (Image 05)

A line graph presenting percent change over time from baseline to 24 months across different treatment groups, including placebo and three active treatment levels indicated by patch sizes of 7.75 cm², 15.5 cm², 18.6 cm², and 31 cm². The X-axis shows visit times (baseline, 6, 12, 18, 24 months) and the Y-axis represents percent change.*

FDA Label Image

Figure 4 Mean Percent Change From Baseline In Total Hip By Treatment And Time Last Observation Carried Forward (Image 06)

A line graph depicting percentage change over time from baseline to 24 months. The x-axis shows patient visits at baseline, 6, 12, 18, and 24 months, while the y-axis indicates percentage change. Multiple lines represent treatment groups with placebo and transdermal patch sizes (7.75 cm², 15.5 cm², 18.6 cm², and 31 cm²).*

FDA Label Image

Instructions For Use Figure A (Image 07)

Packaging label for Estradiol transdermal system, USP, indicating it is a continuous delivery once-weekly patch. The label states contents as 1 system and displays the Mylan Pharmaceuticals Inc. logo. No specific strength is shown in the image.*

FDA Label Image

Instructions For Use Figures B And C (Image 08)

Instructional diagram for estradiol transdermal system patch showing the patch packaging with tear notches and additional tear notches. It illustrates the process of opening the pouch, including pulling apart the packaging at the tear notches, and carefully removing the estradiol patch. The packaging displays the product name 'Estradiol Transdermal System, USP Continuous Delivery (Once-Week)' and the Mylan logo.*

FDA Label Image

Instructions For Use Figures D And E (Image 09)

Illustrations showing the application of an Estradiol transdermal patch. Figure D is a close-up of the patch with a protective liner labeled. Figure E shows hands peeling off the protective liner from the patch prior to application to the skin.*

FDA Label Image

Instructions For Use Figures F And G (Image 10)

Illustration showing application sites for the Estradiol transdermal patch. Figure F depicts placement on the abdomen, and Figure G shows placement on the buttocks. Both figures demonstrate how a hand positions the patch on the skin.*

FDA Label Image

Instructions For Use Figure H (Image 11)

Illustration depicting the placement of an Estradiol transdermal patch on the upper arm or shoulder area of a person's body, showing proper application location for the patch.*

FDA Label Image

Estradiol Transdermal System, Usp 0.025 mg/day Carton Label (Image 12)

Carton for Estradiol 0.025 mg/day transdermal patch by Mylan Pharmaceuticals Inc. The packaging indicates it contains 4 transdermal systems for continuous once-weekly delivery. Label includes dosage strength, active ingredient, usage instructions, and storage information. The design is predominantly blue and white with purple text highlighting the strength.*

FDA Label Image

Estradiol Transdermal System, Usp 0.0375 mg/day Carton Label (Image 13)

Estradiol 0.0375 mg/day transdermal system patch carton from Mylan Pharmaceuticals Inc. The label indicates it is a continuous delivery system for once-weekly use with 4 transdermal systems included. The packaging includes storage instructions, ingredient details, and usage warnings on a primarily blue and white background.*

FDA Label Image

Estradiol Transdermal System, Usp 0.05 mg/day Carton Label (Image 14)

Estradiol 0.05 mg/day transdermal patch packaging label by Mylan Pharmaceuticals Inc. The label states it is a continuous delivery system (once-weekly) containing estradiol USP hemihydrate. The package holds 4 transdermal systems and includes storage instructions, usage directions, and drug contents details. The design features red and black text on a white and blue background with the Mylan logo.*

FDA Label Image

Estradiol Transdermal System, Usp 0.06 mg/day Carton Label (Image 15)

Estradiol 0.06 mg/day transdermal system label by Mylan Pharmaceuticals Inc. The label indicates a continuous delivery (once-weekly) patch with instructions to store between 20° to 25°C and keep out of reach of children. The packaging includes warnings, inactive ingredients, and manufacturer information.*

FDA Label Image

Estradiol Transdermal System, Usp 0.075 mg/day Carton Label (Image 16)

The carton label for Estradiol transdermal system patch from Mylan Pharmaceuticals Inc. shows the 0.075 mg/day strength. It is a once-weekly continuous delivery patch. The label highlights contents and inactive ingredients, storage instructions, dosage note, and warnings for transdermal use only. The packaging specifies four transdermal systems per carton and includes barcodes and manufacturer details.*

FDA Label Image

Estradiol Transdermal System, Usp 0.1 mg/day Carton Label (Image 17)

Estradiol 0.1 mg/day transdermal system patch, continuous delivery (once-weekly), from Mylan Pharmaceuticals Inc. The packaging indicates a set of 4 transdermal systems. The label includes storage instructions, dosage directions, and a list of inactive ingredients. The product is for transdermal use only and marked Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.